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Abstract 
The Office of Vaccines Research and Review (OVRR) at the Center for Biologics Evaluation and Research (CBER), Food and 
Drug Administration (FDA) regulates preventative and therapeutic vaccines for infectious disease indications for use in humans. 
The framework for regulation of biological products includes Statutes (e.g. The U.S. Food, Drug and Cosmetic Act and the 
Public Health Service Act), regulations as defined in the Code of Federal Regulations (CFR) and guidance documents. Approval 
of a biologics license for a product, including vaccines, is based on a demonstration of safety, purity, and potency and assurance 
that the facility for manufacture, processing, and packaging meets standards to ensure that product released for distribution is 
safe, pure and potent. The regulatory definitions of safety, purity and potency are detailed in Title 21 of the Code of Federal 
regulations (CFR) Part 600. All manufacturing information including tests for safety, purity, and potency for a particular product 
must be documented in the Biologics License Application (BLA). Potency testing may be performed on the final bulk sample or 
final container sample and may consist of either in vivo or in vitro tests or both. To change a potency or safety test post-licensure 
requires a Supplement to the License and data to support a modified or alternative test. CBER encourages the development and 
use of appropriate alternative methods for vaccine safety and potency testing. 
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1. Introduction 
The Office of Vaccines Research and Review (OVRR) at the Center for Biologics Evaluation and Research 
(CBER), U.S. Food and Drug Administration (FDA) is responsible for the licensure of certain biological products, 
including preventive and therapeutic vaccines for infectious disease indications for use in humans. Vaccines 
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licensed for human use must be safe, pure, and potent and manufactured consistently according to Good 
Manufacturing Practices.  
The purpose of this paper is to provide an understanding of the regulation of human vaccines in the United States, 
focusing on tests for safety and potency performed on final bulk or final container product. 
2. Legal statutes for FDA regulated biological products  
The U.S. Public Health Service Act (PHS Act) and certain sections of the U.S. Food, Drug and Cosmetic Act 
(FD&C Act) provide FDA the authority to regulate vaccines. Section 351 of the Public Health Service Act (42 USC 
262) states that a biologics application can be approved based on a demonstration that “(I) the biological product 
that is the subject of the application is safe, pure, and potent; and (II) the facility in which the biological product is 
manufactured, processed, packed or held meets standards designed to assure that the biological product continues to 
be safe, pure, and potent...” 
The concept that a biological product should be safe, pure, and potent dates from the 1902 Biologics Control Act 
(BC Act), one of the precursors to the PHS Act. The BC Act was passed after a number of tragedies, including in 
1901 the death of 13 children who had received equine-derived diphtheria antitoxin contaminated with tetanus toxin. 
A subsequent investigation discovered that the horse from which the serum had been obtained had contracted 
tetanus and had been killed. Unfortunately, the serum from that horse had not been destroyed. During discussion of 
the legislation several points were raised including the need for control of manufacturing establishments, that there 
were few remedial measures available if the administered products were impure or unsafe and that control of 
potency was very important because use of an ineffective product may lead to the death of the recipient (Division of 
Biologics Standards, NIH. Legislative History of the Regulation of Biological Products (2nd printing). Bethesda, 
MD, NIH, 1968 as described in Vaccines 5th Edition, Plotkin SA, Orenstein WA and Offit PA Eds., 2008). 
3. FDA regulations and guidance documents for biological products  
Title 21 of the Code of Federal Regulations (CFR) contains the regulations through which FDA implements the 
PHS Act and the FD&C Act. Title 21 CFR Parts 600-680 contains the regulations specifically applicable to 
biological products including vaccines. The legal definitions of safety, purity, and potency are stated in § CFR 
600.3: 
Safety is defined as: “…the relative freedom from harmful effect to persons affected, directly or indirectly, by a 
product when prudently administered, taking into consideration the character of the product in relation to the 
condition of the recipient at the time.” 
Purity is defined as: “…relative freedom from extraneous matter in the finished product, whether or not harmful 
to the recipient or deleterious to the product. Purity includes but is not limited to relative freedom from residual 
moisture or other volatile substances and pyrogenic substances.” 
Potency is: “…the specific ability or capacity of the product, as indicated by appropriate laboratory tests or by 
adequately controlled clinical data obtained through administration of the product in the manner intended, to effect a 
given result.” 
All tests for safety, purity, and potency for a particular product are documented in the license, and assure that the 
product meets applicable standards for safety, purity, and potency at the time of licensure and post-licensure. Until 
1996 Title 21 of the CFR contained in Part 620 – Additional Standards for Bacterial Products - and in Part 630 – 
Additional Standards for Viral Vaccines - prescriptive tests for several bacterial and viral vaccines. These were 
revoked for the following reasons stated in the Federal Register notice: “The …regulations … are more 
appropriately specified in the product license. As currently written, these regulations can be too restrictive for 
certain products because they specify particular methodologies or standards when alternatives may be available that 
provide the same level of assurance of safety, purity, and potency. Allowing the product standards to be specified in 
the product license will give manufacturers the flexibility to improve their products and make appropriate changes to 
their methods of manufacture. Therefore, these regulations may be unduly restrictive and are duplicative and 
unnecessary.” (Federal Register, Vol. 60. No 198, October 13, 1995 and Vol. 61. No 149, August 1, 1996). 
One safety test, the General Safety Test (GST) for detection of extraneous toxic contaminants, is described in the 
regulations (§ CFR 610.11). Although certain biological products are exempt from the requirement to perform a 
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GST, vaccines are not. In 1998 FDA published a direct final rule and a companion proposed rule (April 20, 1998, 63 
FR 19399 and 19431, respectively) to revise the general safety requirements for biological products. This revision 
would have amended the regulations to exempt cellular therapy products from the GST requirement and to add an 
administrative procedure for manufacturers to request exemptions from performing the GST. However, significant 
adverse comments on the administrative procedure provision were received. Therefore, in August 1998 FDA 
confirmed that § CFR 610.11 had been revised to add ‘‘cellular therapy products’’ to the list of products exempted 
from the GST (August 5, 1998 63 FR 41718). However, based on the adverse comments received FDA withdrew 
the proposed revision that provided a general administrative procedure for requesting and obtaining exemptions 
from the GST.  
In 2003 (March 4, 2003, 68 FR 10157), after considering the comments on the direct final rule and the 
companion proposed rule, FDA issued a final rule modifying § 610.11 to include a provision that manufactures may 
request an exemption from the GST. These requests must be submitted in a biologics license application or in a 
supplement to a license application and include information establishing that because of the mode of administration, 
the method of preparation or the special nature of the product a test of general safety is unnecessary to assure the 
safety, purity, and potency of the product or that the test cannot be performed. Vaccine manufacturers must apply 
for and receive a waiver of the requirement to perform the GST. Since this revision of § 610.11 FDA has granted 
exemptions to vaccine manufacturers from the requirement to perform the GST. 
The regulations (§ 610.1) state: “No lot of any licensed product shall be released by the manufacturer prior to 
completion of tests for conformity with standards applicable to such product…” For U.S.–licensed vaccines, final 
bulk or final container tests for safety and potency described in the license must be performed on each lot of 
product. Specific safety tests described in license applications include, for example, the Histamine Sensitization Test 
for pertussis toxin and the test for endotoxin. For the tetanus and diphtheria toxoid containing vaccines the safety 
and potency tests performed on final bulk or final container material are described in Guidance documents. 
Guidance documents represent FDA’s current thinking about a topic. In contrast to regulations they are not binding 
on FDA or regulated industry. 
4. Alternative test development to reduce, refine, and replace the use of animals  
As noted above, prescriptive tests for potency and safety are not, with the exception of the GST, included in the 
regulations. Therefore, manufacturers can propose alternative tests that reduce, refine, or replace the use of animals. 
In considering the use of alternative test it is important for the manufacturer to address the relevance of the test, to 
provide data to support the use of the alternative and to adequately validate the test for its intended use. The goal is 
to ensure the licensure and continued availability of safe, pure, and potent vaccines. 
If a manufacturer wants to use an alternative safety or potency test from that described in the license the 
manufacturer must submit a supplement to the license and provide data demonstrating that the change does not 
adversely affect the safety or effectiveness of the product. The regulations in § 601.12 provide the requirements for 
reporting such changes for licensed biological products, including vaccines, to the FDA. As described in the 
regulations and in the accompanying Guidance document (Guidance for Industry: Changes to an Approved 
Application: Biological Products, 1997) there are three reporting categories: 
1) Changes that have a substantial potential to have an adverse effect on the identity, strength, quality, purity, or 
potency of the product as they may relate to the safety or effectiveness of the product require submission of a 
supplement and approval by FDA prior to distribution of the product made using the change;  
2) Changes that have a moderate potential to have an adverse effect on the identity, strength, quality, purity, or 
potency of the product as they may relate to the safety or effectiveness of the product require submission of a 
supplement to FDA at least 30 days prior to distribution of the product made using the change; and  
3) Changes that have minimal potential to have an adverse effect on the identity, strength, quality, purity, or 
potency of the product as they may relate to the safety or effectiveness of the product may be described by the 
applicant in an annual report.  
A request to use an alternative potency test or safety test would be considered to be a change in the 
manufacturing process with substantial potential to have an adverse effect on the safety or effectiveness of the 
product. Thus, submission of a supplement and FDA approval of the change would be required prior to distribution 
of product made using the change. 
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5. Conclusion 
Many of the animal based safety or potency tests currently in use have a long record of use and have ensured the 
availability of safe and effective vaccines. Changing established practice requires scientific and monetary 
investment. The vaccine marketplace is global. Thus, manufacturers considering changes in safety or potency tests 
to reduce, refine, or replace the use of animals must consider whether these changes will be acceptable to regulatory 
agencies around the world. Regulatory agencies can facilitate the adoption of alternative tests by working together to 
ensure these alternative methods will have global acceptance. 
